Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
|Articles|October 19, 2012
Go-For-The-Glory: This Week's Primary Care Quiz
Skills Quiz: Melanoma; Figurate erythema; Necrobiosis lipoidica
Advertisement
Test your skills in this 5-question quiz, starting here.
QUESTION 1:
QUESTION 2:
QUESTION 3:
QUESTION 4:
QUESTION 5:
ANSWER KEY:
Question 1. Answer: c
Question 2. Answer: d
Question 3. Answer: d
Question 4. Answer: b
Question 5. Answer: c
Advertisement
Related to this article
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.
Axsome has launched the SUMMIT phase 3 clinical trial evaluating AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.
Advertisement
Advertisement
Trending on Patient Care Online
1
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
2
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
3
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
4
Unmet Needs and Mechanisms Behind Newer Agitation Therapies
5